Compare ACCL & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACCL | EVAX |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | Hong Kong | Denmark |
| Employees | 22 | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.9M | 23.6M |
| IPO Year | N/A | 2020 |
| Metric | ACCL | EVAX |
|---|---|---|
| Price | $2.29 | $2.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | ★ 24.6K | 13.1K |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $328.20 |
| P/E Ratio | $17.13 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.23 | $2.52 |
| 52 Week High | $5.00 | $12.15 |
| Indicator | ACCL | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 79.16 | 36.10 |
| Support Level | $1.31 | N/A |
| Resistance Level | $2.34 | $3.61 |
| Average True Range (ATR) | 0.11 | 0.14 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 88.04 | 14.42 |
Acco Group Holdings Ltd is a holding company. Through its Operating Subsidiaries, it is a multi-disciplinary, IT-driven corporate service provider with a presence in Hong Kong and Singapore. Under the Accolade brand, it specializes in offering corporate secretarial services and accounting services in Hong Kong, as well as intellectual properties (IP) registration services in Singapore. Leveraging developed IT solutions, It provides comprehensive, reliable and professional support to its clients, enabling them to focus on their core business activities while it manages and handles their corporate compliance needs. Its clientele ranges from individual clients, small and medium-sized enterprises to multinational corporations, reflecting its ability to cater to diverse business needs.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.